GLP-1 analogs, such as Liraglutide and Exendin-4, unlike endogenously produced GLP-1, are not rapidly degraded by Dipeptidyl peptidase-4 (DPP-4) and, therefore, can induce sustained therapeutic actions, that otherwise would not be possible due to the exceedingly short half-life of endogenous GLP-1 in circulation
Can't find the exact medicine
"So the question is does it correlate to the medication [or] does it correlate to the patient population?" he said
The results, on the other hand, are impossible to ignore
One line summary of the article The article explores the potential of GLP-1 receptor agonists as a novel treatment option for alcohol use disorder (AUD) by highlighting both preclinical and clinical research findings
Always take berberine with meals to help minimize digestive side effects